Recovery outcomes of schizophrenia patients treated with paliperidone palmitate in a community setting: patient and provider perspectives on recovery

Abstract

Objectives:This study evaluated the effect of paliperidone palmitate long-acting injectable (LAI) antipsychotic on recovery-oriented mental health outcomes from the perspective of healthcare providers and patients during the treatment of patients with schizophrenia or schizoaffective disorders. Methods:Archival data for patients with a primary diagnosis of schizophrenia or schizoaffective disorder receiving !6 months of paliperidone palmitate LAI were retrieved from the electronic medical records system at the Mental Health Center of Denver. Mental health recovery was assessed from both a provider's (Recovery Markers Inventory [RMI]) and patient's (Consumer Recovery Measure [CRM]) perspective. A three-level hierarchical linear model (HLM) was utilized to determine changes in CRM and RMI scores by including independent variables in the models: intercept, months from treatment (slope), treatment time period (pretreatment and treatment), age, gender, primary diagnosis, substance abuse diagnosis, concurrent medications, and adherence to paliperidone palmitate LAI. Results:A total of 219 patients were identified and included in the study. Results of the final three-level HLMs indicated an overall increase in CRM scores (p50.05), an overall increase (p50.01), and an increased rate of change (p50.05) in RMI scores during the paliperidone palmitate LAI treatment period vs the pre-treatment period. Limitations:This study contained a retrospective, non-comparative design, and did not adjust for multiplicity Conclusions:The current study demonstrates that changes in recovery-oriented mental health outcomes can be detected following the administration of a specific antipsychotic treatment in persons with schizophrenia or schizoaffective disorders. Furthermore, patients receiving paliperidone palmitate LAI can effectively improve recovery-oriented outcomes, thereby supporting the drug's use as schizophrenia treatment from a recovery-oriented perspective.

Effectiveness of 1-year treatment with long-acting formulation of aripiprazole, haloperidol, or paliperidone in patients with schizophrenia: retrospective study in a real-world clinical setting

“…The efficacy of PP has been supported by many studies, such as the PALMFlexS multicenter, open-label, flexible-dose trial, which explored tolerability, safety, and treatment response in three arms of acute and nonacute but symptomatic adult patients previously unsuccessfully treated with LAIs or oral APDs 38–40. The effectiveness of PP-OM in comparison with previous APD treatments has been shown in terms of quality of life from a recovery-oriented perspective 41. PP-OM has also shown low rates of dropout in naturalistic cohort studies, with an acceptably safe metabolic impact 42–44…”

Short-term rehospitalizations in young adults with schizophrenia treated with once-monthly paliperidone palmitate or oral atypical antipsychotics: a retrospective analysis

“…Although the effects of PP1M on the risk of relapse are well documented 17,[21][22][23][24] , there is limited real-world information on relapse that is specific to young adult populations with schizophrenia in the US 25 . Rehospitalizations, a parameter used as a quality-of-care measure for US providers and payers 26 , are an important marker of relapse and disease burden in patients with schizophrenia 6,27 .…”